Oncology drug development across the US, China, and Europe is converging on the same 18-month regulatory window. A cluster of antibody-drug conjugate (ADC) combination trials will produce read-outs between late 2026 and end-2027, compressing binary risk for investors globally.
China has already delivered a proof point. HUTCHMED and Innovent secured NMPA approval for ELUNATE (fruquintinib) combined with TYVYT (sintilimab) in locally advanced or metastatic renal cell carcinoma.4 Professor Dingwei Ye cited the combination's "potential to address the pressing medical needs" of RCC patients.4 The decision validates precision combination regimens outside the US and adds a milestone-payment dimension for China-partnered developers worldwide.
In the US, Crescent Biopharma's CR-001 — a PD-1×VEGF bispecific antibody — is enrolling in the ASCEND trial. Paired ADC combination studies are planned alongside ASCEND across multiple solid tumor types. Initial data is expected in Q1 2027.1
SystImmune presented izalontamab brengitecan data at ASCO 2026. Chief Medical Officer Jie D'Elia described the company's capacity to "rapidly translate innovative science into differentiated therapies for patients with high unmet need worldwide."2 Exelixis also presented multiple datasets at ASCO 2026. CMO Dana T. Aftab framed the data as evidence of "improving the standards of care for patients with cancer."3
A fourth modality is entering the mix. Aktis Oncology is advancing targeted alpha therapy — radiopharmaceuticals — alongside ADCs, bispecifics, and checkpoint inhibitors. The expansion broadens addressable combination pairings for platform companies operating across multiple markets.
The commercial logic is consistent across geographies: single-agent ADCs hit ceiling effects in heavily pre-treated patients. Combination regimens target resistance pathways that monotherapy cannot reach. Companies demonstrating synergy in Phase 1/2 front-line settings carry the strongest re-rating potential — whether their primary market is the FDA, NMPA, or EMA.
The 2026–2027 window concentrates that risk. A failed readout reprices an entire platform. A positive one — especially front-line or in a large indication — can trigger swift market re-rating before Phase 3 data arrives. Portfolio managers holding multiple names across this global cluster face correlated event exposure heading into the second half of 2026.
